NA
VIRX

NewEdge Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

NewEdge Advisors’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14
Closed -$8 – 3972
2024
Q2 		$8 Hold
14
– – ﹤0.01% 3756
2024
Q1 		$14 Hold
14
– – ﹤0.01% 3772
2023
Q4 		$8 Hold
14
– – ﹤0.01% 3718
2023
Q3 		$15 Buy
+14
New +$19 ﹤0.01% 3433

Other funds holding VIRX

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return

NewEdge Advisors's VIRX Position: Q3 2024 in Review

NewEdge Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2024, closing a stake of 14 shares — an estimated $8 sold.

NewEdge Advisors first reported a position in VIRX in Q3 2023 and held it in 4 quarters. The position peaked at $15 in Q3 2023. 38 funds tracked by Wall St. Rank hold VIRX as of Q3 2024.

  • NewEdge Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • NewEdge Advisors sold 14 Viracta Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $8.
  • NewEdge Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q3 2023 and held it in 4 quarters.
  • NewEdge Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $15 in Q3 2023.
  • 38 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2024.

Based on NewEdge Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.